Evidence map›Paper›PMID 30528745›Full record

ReviewBiological psychiatry2019

Leveraging Neuroplasticity to Enhance Adaptive Learning: The Potential for Synergistic Somatic-Behavioral Treatment Combinations to Improve Clinical Outcomes in Depression.

Samuel T Wilkinson, Paul E Holtzheimer, Shan Gao, David S Kirwin, Rebecca B Price

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biological psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Psilocybin-assisted neurofeedback for the improvement of executive functions: a randomized semi-naturalistic-lab feasibility study.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2024
    Trial
  10. Trial
  11. Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: preliminary evidence.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021
    Trial
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Samuel T WilkinsonDepartment of Psychiatry, Yale School of Medicine and Yale Psychiatric Hospital, New Haven, Connecticut.
Paul E HoltzheimerNational Center for PTSD, Executive Division, White River Junction VA Medical Center, White River Junction, Vermont; Department of Psychiatry and Surgery, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.
Shan GaoDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania.
David S KirwinDepartment of Psychiatry, Yale School of Medicine and Yale Psychiatric Hospital, New Haven, Connecticut.
Rebecca B PriceDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania. Electronic address: rebecca.price@stanfordalumni.org.

Funding

Yale-CORE Career Development Program in Patient-Centered Outcomes ResearchK12HS023000 · AHRQ · YALE UNIVERSITY · PI KRUMHOLZ, HARLAN MARC · 2014 to 2018
$3.4M
Testing a Synergistic, Neuroplasticity-Based Intervention for Depressive NeurocognitionR01MH113857 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PRICE, REBECCA · 2017 to 2021
$2.4M
Neural Dimensions of Attention Bias Modification for Transdiagnostic AnxietyK23MH100259 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PRICE, REBECCA · 2013 to 2017
$788k
AHRQ HHS K12 HS023000NIMH NIH HHS K23 MH100259NIMH NIH HHS L30 MH111000NIMH NIH HHS R01 MH113857
6 · The paper itself

Abstract

Until recently, therapeutic development in psychiatry was targeted solely toward symptom reduction. While this is a worthwhile goal, it has yielded little progress in improved therapeutics in the last several decades in the field of mood disorders. Recent advancements in our understanding of pathophysiology suggests that an impairment of neuroplasticity may be a critical part of the development of neuropsychiatric disorders. Interventions that enhance or modulate neuroplasticity often reduce depressive symptoms when applied as stand-alone treatments. Unfortunately, when treatments are discontinued, the disease state often returns as patients relapse. However, treatments that enhance or modulate plasticity not only reduce symptom burden, but also may provide an opportune window wherein cognitive or behavioral interventions could be introduced to harness a state of enhanced neuroplasticity and lead to improved longer-term clinical outcomes. Here, we review the potential of synergistically combining plasticity-enhancing and behavioral therapies to develop novel translational treatment approaches for depression. After reviewing relevant neuroplasticity deficits in depression, we survey biological treatments that appear to reverse such deficits in humans, including N-methyl-D-aspartate receptor modulators (ketamine, D-cycloserine), electroconvulsive therapy, and transcranial brain stimulation. We then review evidence that either directly or indirectly supports the hypothesis that a robust enhancement of neuroplasticity through these methods might promote the uptake of cognitive and behavioral interventions to enhance longer-term treatment outcomes through a synergistic effect. We identify key missing pieces of evidence and discuss future directions to enhance this emerging line of research.

Indexed as

Antidepressive AgentsBehavior TherapyCombined Modality TherapyDepressionElectroconvulsive TherapyHumansNeuronal PlasticityTranscranial Magnetic StimulationAntidepressive AgentsDepressionElectroconvulsive therapyKetamineNeuromodulationNeuroplasticityTranscranial magnetic stimulation

Identifiers

PMID30528745
PMCPMC6380941

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.